Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001054760 | SCV001219110 | likely benign | Lethal congenital glycogen storage disease of heart | 2023-12-06 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV001177642 | SCV001341885 | likely benign | Cardiomyopathy | 2019-12-09 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002355041 | SCV002649943 | uncertain significance | Cardiovascular phenotype | 2022-05-27 | criteria provided, single submitter | clinical testing | The p.P198R variant (also known as c.593C>G), located in coding exon 4 of the PRKAG2 gene, results from a C to G substitution at nucleotide position 593. The proline at codon 198 is replaced by arginine, an amino acid with dissimilar properties. This variant was described in three individuals from a PRKAG2 study, at least some of whom had related cardiac findings but details were limited (Lopez-Sainz A et al. J Am Coll Cardiol, 2020 07;76:186-197). This variant was also reported as de novo in one individual from a neurodevelopmental cohort; however, cardiac phenotype was not provided, and this individual had additional de novo variants detected (Turner TN et al. Am J Hum Genet, 2019 12;105:1274-1285). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |